MA38318A1 - Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer - Google Patents

Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer

Info

Publication number
MA38318A1
MA38318A1 MA38318A MA38318A MA38318A1 MA 38318 A1 MA38318 A1 MA 38318A1 MA 38318 A MA38318 A MA 38318A MA 38318 A MA38318 A MA 38318A MA 38318 A1 MA38318 A1 MA 38318A1
Authority
MA
Morocco
Prior art keywords
ionizing radiation
inorganic nanoparticles
cancer
compositions
treatment
Prior art date
Application number
MA38318A
Other languages
English (en)
Inventor
Agnès Pottier
Laurent Levy
Elsa Borghi
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MA38318A1 publication Critical patent/MA38318A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1087—Ions; Protons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1089—Electrons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des nanoparticules inorganiques activables pouvant être utilisées dans le secteur de la santé, en particulier de la santé humaine, pour perturber, modifier ou détruire des cellules, tissus ou organes cibles cancéreux. Elle concerne plus particulièrement des nanoparticules pouvant générer un effet thérapeutique significativement efficace, lorsqu'elles sont concentrées à l'intérieur de la tumeur et exposées à des rayonnements ionisants. L'invention concerne également des compositions pharmaceutiques contenant un ensemble de nanoparticules telles que définies précédemment, ainsi que leurs utilisations.
MA38318A 2013-01-25 2014-01-24 Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer MA38318A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305087 2013-01-25
PCT/EP2014/051367 WO2014114732A1 (fr) 2013-01-25 2014-01-24 Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA38318A1 true MA38318A1 (fr) 2017-02-28

Family

ID=47710064

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38318A MA38318A1 (fr) 2013-01-25 2014-01-24 Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer

Country Status (22)

Country Link
US (4) US10098952B2 (fr)
EP (1) EP2948179B1 (fr)
JP (2) JP6619231B2 (fr)
KR (2) KR102385193B1 (fr)
CN (1) CN105120897B (fr)
AR (1) AR094577A1 (fr)
AU (1) AU2014209899B2 (fr)
BR (1) BR112015017490A2 (fr)
CA (3) CA2897362C (fr)
CY (1) CY1121838T1 (fr)
EA (1) EA034242B1 (fr)
IL (1) IL239767B (fr)
MA (1) MA38318A1 (fr)
MX (1) MX369664B (fr)
PL (1) PL2948179T3 (fr)
RS (1) RS59042B1 (fr)
SG (1) SG11201505277VA (fr)
SI (1) SI2948179T1 (fr)
TW (1) TW201442726A (fr)
UA (1) UA116007C2 (fr)
WO (1) WO2014114732A1 (fr)
ZA (1) ZA201505510B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2790682T3 (pl) 2011-12-16 2019-08-30 Nanobiotix Nanocząstki zawierające materiał metaliczny i materiał tlenku hafnu, ich wytwarzanie i zastosowanie
SI2948179T1 (sl) 2013-01-25 2019-09-30 Nanobiotix Sestavki, ki obsegajo nanodelce hafnij (IV) oksida ali renij (IV) oksida v kombinaciji z ionizirajočimi sevanji za zdravljenje raka
WO2015102680A2 (fr) 2013-09-11 2015-07-09 The Board Of Trustees Of The Leland Stanford Junior University Méthodes et systèmes de modulation de l'intensité d'un faisceau pour faciliter des traitements radiothérapeutiques rapides
EP2886128A1 (fr) * 2013-12-20 2015-06-24 Nanobiotix Compositions pharmaceutiques comportant des nanoparticules, leur préparation et leur utilisation
WO2016189125A1 (fr) 2015-05-28 2016-12-01 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
KR20190107026A (ko) * 2016-12-21 2019-09-18 나노비오?스 뇌 성능을 향상시키거나 스트레스를 치료하는데 사용하기 위한 나노입자
CN115590955A (zh) * 2016-12-21 2023-01-13 纳米生物技术公司（Fr） 用于治疗神经元障碍的纳米粒子
EP3424533A1 (fr) * 2017-07-05 2019-01-09 Nh Theraguix Procédés de traitement de la dépendance
WO2019018813A1 (fr) * 2017-07-21 2019-01-24 Varian Medical Systems, Inc. Procédés d'utilisation de rayonnement à débit de dose ultra élevé et d'agents thérapeutiques
US20220249389A1 (en) 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
WO2021011496A1 (fr) * 2019-07-12 2021-01-21 Oregon Health & Science University Constructions immunothérapeutiques et leurs procédés d'utilisation
CA3139714A1 (fr) 2019-07-12 2021-01-21 Wassana Yantasee Constructions therapeutiques pour la co-administration d'un inhibiteur de la kinase mitotique et d'un inhibiteur des points de controle immunitaire
WO2021215952A1 (fr) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Procédé de production de particules de bactériophages de la famille levivirus
FR3160407A1 (fr) 2024-03-25 2025-09-26 Gcs Institut De Cancerologie Strasbourg Europe Complexe peptidique radiosensibilisant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006244A2 (fr) 1998-07-30 2000-02-10 Hainfeld James F Particules metalliques de chargement dans des vesicules membranaires cellulaires et particule metallique utilisee pour l'imagerie et la therapie
CA2428805A1 (fr) * 2000-11-20 2002-05-23 Oncolytics Biotech Inc. Procede d'apport optimal d'un virus a une masse de tumeur solide
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
FR2884149B1 (fr) * 2005-04-12 2007-06-08 Henri Mehier Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
EP2130553A1 (fr) 2008-06-05 2009-12-09 Nanobiotix Nanoparticules inorganiques de haute densité pour détruire des cellules in-vivo
US8395131B2 (en) * 2009-06-20 2013-03-12 Xiaodong Wu Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (fr) 2009-07-10 2011-01-19 Nanobiotix Nanoparticules métalliques, leur préparation et utilisations
EP2555800B1 (fr) 2010-04-05 2018-03-21 Nanospectra Biosciences, Inc. Amélioration d'une thérapie par rayonnement par nanoparticules ciblées à z élevé
PL2790682T3 (pl) * 2011-12-16 2019-08-30 Nanobiotix Nanocząstki zawierające materiał metaliczny i materiał tlenku hafnu, ich wytwarzanie i zastosowanie
SI2948179T1 (sl) 2013-01-25 2019-09-30 Nanobiotix Sestavki, ki obsegajo nanodelce hafnij (IV) oksida ali renij (IV) oksida v kombinaciji z ionizirajočimi sevanji za zdravljenje raka

Also Published As

Publication number Publication date
CA2897362C (fr) 2023-02-14
EA034242B1 (ru) 2020-01-21
KR20210027536A (ko) 2021-03-10
CA3251146A1 (fr) 2025-07-09
KR102385193B1 (ko) 2022-04-12
CY1121838T1 (el) 2020-07-31
WO2014114732A1 (fr) 2014-07-31
EA201591378A1 (ru) 2016-04-29
US20210283256A1 (en) 2021-09-16
AU2014209899B2 (en) 2018-05-24
ZA201505510B (en) 2016-12-21
HK1216609A1 (en) 2016-11-25
UA116007C2 (uk) 2018-01-25
AR094577A1 (es) 2015-08-12
CN105120897B (zh) 2017-12-05
TW201442726A (zh) 2014-11-16
JP2016505061A (ja) 2016-02-18
SG11201505277VA (en) 2015-08-28
KR20150108923A (ko) 2015-09-30
US20190008962A1 (en) 2019-01-10
KR102225239B1 (ko) 2021-03-09
MX369664B (es) 2019-11-14
CA2897362A1 (fr) 2014-07-31
SI2948179T1 (sl) 2019-09-30
US11020480B2 (en) 2021-06-01
PL2948179T3 (pl) 2019-10-31
US20150374818A1 (en) 2015-12-31
CN105120897A (zh) 2015-12-02
US10098952B2 (en) 2018-10-16
JP2018168162A (ja) 2018-11-01
US11819548B2 (en) 2023-11-21
CA3179586A1 (fr) 2014-07-31
EP2948179A1 (fr) 2015-12-02
MX2015009409A (es) 2016-03-16
RS59042B1 (sr) 2019-08-30
AU2014209899A1 (en) 2015-07-23
EP2948179B1 (fr) 2019-06-19
JP6619231B2 (ja) 2019-12-11
CA3179586C (fr) 2025-07-08
IL239767A0 (en) 2015-08-31
IL239767B (en) 2018-10-31
BR112015017490A2 (pt) 2017-07-11
US20240100163A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
MA38318A1 (fr) Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer
MA33516B1 (fr) Nanoparticules métalliques, leur préparation et leurs utilisations
NZ703047A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
IN2012DN02018A (fr)
CY1118216T1 (el) Μεθοδοι αγωγης καρκινου
NI201200181A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
NI201200179A (es) Métodos de tratamiento contra el cáncer pancreático
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
MX2016007351A (es) Terapia de combinacion para tratar cancer.
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
BRPI0507039A8 (pt) composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2022001249A (es) Tratamiento de tumores evasivos inmunitarios.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
EP4417197A4 (fr) Composition pharmaceutique pour le traitement du cancer de la prostate résistant à la castration comprenant de la brucéantine et des nanoparticules
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.
NZ709685A (en) Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer